Influenza vaccine response: future perspectives

Mameli, Chiara; D’Auria, Enza; Erba, Paola; Nannini, Pilar; Zuccotti, Gian Vincenzo

doi:10.1080/14712598.2018.1391786

Cited by 14 publications

(11 citation statements)

References 27 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several factors have been hypothesized to have played a role in the diminished vaccine effectiveness, including methodological issues in the studies. 64 …”

Section: Vaccine Types and Production Methodsmentioning

confidence: 99%

Influenza vaccines: Evaluation of the safety profile

Trombetta

Gianchecchi

Montomoli

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs. Vaccines are recommended for children, adults and elderly subjects and have to meet higher safety standards, since they are administered to healthy subjects, mainly healthy children. Although vaccines are strictly monitored before authorization, the possibility of adverse events and/or rare adverse events cannot be totally eliminated.Two main types of influenza vaccines are currently available: parenteral inactivated influenza vaccines and intranasal live attenuated vaccines. Both display a good safety profile in adults and children. However, they can cause adverse events and/or rare adverse events, some of which are more prevalent in children, while others with a higher prevalence in adults.The aim of this review is to provide an overview of influenza vaccine safety according to target groups, vaccine types and production methods.

show abstract

“…Several factors have been hypothesized to have played a role in the diminished vaccine effectiveness, including methodological issues in the studies. 64 …”

Section: Vaccine Types and Production Methodsmentioning

confidence: 99%

Influenza vaccines: Evaluation of the safety profile

Trombetta

Gianchecchi

Montomoli

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Inactivated influenza vaccines (IIVs), which induce limited T cell-mediated immune responses [5], have limited protection efficacy when the seasonal vaccine does not match the circulating strains [6,7]. On the other hand, live attenuated influenza vaccines (LAIVs) usually induce more robust adaptive Band T-cell immune responses associated with better protection against homologous and heterologous influenza viruses [5][6][7]. Despite the multiple advantages of LAIVs, the current LAIV remains restricted for use in healthy children older than two and non-pregnant adults [8].…”

Section: Introductionmentioning

confidence: 99%

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine

et al. 2020

View full text Add to dashboard Cite

Seasonal influenza epidemics remain one of the largest public health burdens nowadays. The best and most effective strategy to date in preventing influenza infection is a worldwide vaccination campaign. Currently, two vaccines are available to the public for the treatment of influenza infection, the chemically Inactivated Influenza Vaccine (IIV) and the Live Attenuated Influenza Vaccine (LAIV). However, the LAIV is not recommended for parts of the population, such as children under the age of two, immunocompromised individuals, the elderly, and pregnant adults. In order to improve the safety of the LAIV and make it available to more of the population, we sought to further attenuate the LAIV. In this study, we demonstrate that the influenza A virus (IAV) master donor virus (MDV) A/Ann Arbor/6/60 H2N2 LAIV can inhibit host gene expression using both the PA-X and NS1 proteins. Furthermore, we show that by removing PA-X, we can limit the replication of the MDV LAIV in a mouse model, while maintaining full protective efficacy. This work demonstrates a broadly applicable strategy of tuning the amount of host antiviral responses induced by the IAV MDV for the development of newer and safer LAIVs. Moreover, our results also demonstrate, for the first time, the feasibility of genetically manipulating the backbone of the IAV MDV to improve the efficacy of the current IAV LAIV.

show abstract

“…There are also adjuvanted seasonal IVs, but in most countries, they are not still licensed for children use. The LAIV is a quadrivalent vaccine containing both viruses A and B (12–14).…”

Section: Introductionmentioning

confidence: 99%

Influenza Vaccination: Effectiveness, Indications, and Limits in the Pediatric Population

et al. 2019

Self Cite

View full text Add to dashboard Cite

Influenza vaccine is considered the most effective way to prevent influenza. Nonetheless, every year vaccine coverage is lower than recommended in the pediatric population. Many factors are supposed to contribute to this phenomenon such as the uncertainty about the indication for vaccination, and the suboptimal vaccine-effectiveness in pediatric age, especially in the youngest children. In this review we discuss the effectiveness, indications, and limits of influenza vaccination in the pediatric population based on the most recent evidences.

show abstract

Influenza vaccine response: future perspectives

Cited by 14 publications

References 27 publications

Influenza vaccines: Evaluation of the safety profile

Influenza vaccines: Evaluation of the safety profile

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine

Influenza Vaccination: Effectiveness, Indications, and Limits in the Pediatric Population

Contact Info

Product

Resources

About